US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
Time:2024-05-22 05:49:21 Source:opinionsViews(143)
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Previous:China sanctions former US lawmaker who supported Taiwan
Next:State Supreme Court and Republican congressional primary elections top Georgia ballots
You may also like
- US defender John Brooks to leave German club Hoffenheim
- Natalie Elphicke says sorry for backing 'naughty Tory' sex attacker ex
- 1 of 3 teens charged with killing a Colorado woman while throwing rocks at cars pleads guilty
- John Swinney clashes with SNP's former Green allies over 'regressive' decision to make anti
- Election deniers moving closer to GOP mainstream as Trump allies fill Congress, report shows
- Sean Burroughs, former MLB player, Little League World Series and Olympic champion, dies at 43
- U.S. House votes to kill motion to remove Speaker Mike Johnson
- Clarence Thomas says critics are pushing 'nastiness'
- No more cute snaps of Mt Fuji. A screen is up in a Japanese town to prevent tourist crowds